三阴性乳腺癌的治疗现状及进展

Treatment Status and Progress of Triple Negative Breast Cancer

摘要: 乳腺癌是女性最常见的恶性肿瘤之一。在我国占全身恶性肿瘤的7%~10%，呈逐年上升趋势。部分大城市报告乳腺癌占女性恶性肿瘤之首位。三阴性乳腺癌(Triple-Negative Breast Cancer, TNBC)是一种特殊类型的乳腺癌，其特点是在免疫组化检测中，雌激素受体(ER)、孕激素受体(PR)以及人表皮生长因子受体2 (HER2)均为阴性。本文就三阴性乳腺癌的研究现况、化学治疗、分子分型与靶向治疗、内分泌治疗进行综述。

Abstract: Breast cancer is one of the most common malignant tumors in women. In China, it accounts for 7%~10% of the total malignant tumors, showing an increasing trend year by year. Some large cities report breast cancer as the number one malignancy among women. Triple-Negative Breast Cancer (TNBC) is a specific type of breast cancer characterized by a negative immunohistochemical test for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This article reviews the research status, chemotherapy, molecular typing, targeted therapy and endocrine therapy of triple-negative breast cancer.